Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well atezolizumab when given with glycosylated recombinant
human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has
spread to nearby tissue or lymph nodes (locally advanced), cannot be removed by surgery
(inoperable), or has spread to other places in the body (metastatic). Immunotherapy with
monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. CYT107 is a
biological product naturally made by the body that may stimulate the immune system to destroy
tumor cells. Giving atezolizumab and CYT107 may work better in treating patients with locally
advanced, inoperable, or metastatic urothelial carcinoma compared to atezolizumab alone.